0001144204-15-028480.txt : 20150507 0001144204-15-028480.hdr.sgml : 20150507 20150507172145 ACCESSION NUMBER: 0001144204-15-028480 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20150323 FILED AS OF DATE: 20150507 DATE AS OF CHANGE: 20150507 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Protalix BioTherapeutics, Inc. CENTRAL INDEX KEY: 0001006281 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 650643773 STATE OF INCORPORATION: FL FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2 SNUNIT ST STREET 2: SCIENCE PARK, POB 455 CITY: CARMIEL STATE: L3 ZIP: 20100 BUSINESS PHONE: 972-4-988-9488 MAIL ADDRESS: STREET 1: 2 SNUNIT ST STREET 2: SCIENCE PARK, POB 455 CITY: CARMIEL STATE: L3 ZIP: 20100 FORMER COMPANY: FORMER CONFORMED NAME: ORTHODONTIX INC DATE OF NAME CHANGE: 19980422 FORMER COMPANY: FORMER CONFORMED NAME: EMBASSY ACQUISITION CORP DATE OF NAME CHANGE: 19960124 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Almon Einat Brill CENTRAL INDEX KEY: 0001385116 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33357 FILM NUMBER: 15843066 MAIL ADDRESS: STREET 1: C/O PROTALIX BIOTHERAPEUTICS, INC. STREET 2: 2 SNUNIT ST, SCIENCE PARK, POB 455 CITY: CARMIEL STATE: L3 ZIP: 20100 4 1 v409796_4.xml OWNERSHIP DOCUMENT X0306 4 2015-03-23 0 0001006281 Protalix BioTherapeutics, Inc. PLX 0001385116 Almon Einat Brill C/O PROTALIX BIOTHERAPEUTICS, INC. 2 SNUNIT ST, SCIENCE PARK, POB 455 CARMIEL L3 20100 ISRAEL 0 1 0 0 SVP, Product Development Stock Options (Right to Buy) 1.72 2015-03-23 4 A 0 250000 0 A 2025-03-23 Common Stock 250000 250000 D 25% of the shares of common stock underlying the stock options shall vest on the first one-year anniversary of the date of grant and the remaining 75% of the shares of common stock underlying the stock options shall vest in 12 equal quarterly installments commencing on such anniversary. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., 2006 Stock Incentive Plan, as amended. Does not include options to purchase 311,272 shares of common stock at an exercise price equal to $5.00 per share that expire on February 7, 2018 and options to purchase 130,000 shares of common stock at an exercise price equal to $6.90 per share that expire on February 25, 2020. /s/ Yossi Maimon, POA 2015-05-07